ENDRA Life Sciences Amends Merger Terms, Sets Cash Floor
ENDRA Life Sciences has amended its merger agreement with Renergen, resetting the minimum cash requirement to approximately $3.8 million and removing the classified board provision.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.